Aquinox(NLTX) - 2025 Q4 - Annual Report

Financial Overview - The company has raised approximately $552.1 million in aggregate net proceeds since its inception, with net losses of $90.4 million and $75.1 million for the years ended December 31, 2025 and 2024, respectively[29]. - As of December 31, 2025, the company had an accumulated deficit of $352.6 million and cash, cash equivalents, and short-term investments totaling $269.0 million[29]. - The company has not generated any commercial revenue from product sales and expects to incur significant development and marketing costs prior to achieving profitability[31]. Clinical Trials and Development - The ongoing registrational trial of NGN-401 for Rett syndrome has enrolled 100% of participants, with over 50% dosed, and is expected to complete dosing in Q2 2026[27]. - NGN-401 is designed to be administered via a one-time intracerebroventricular (ICV) procedure, targeting key areas of the brain for optimal biodistribution[27]. - The company has completed a Phase 1/2 clinical trial of NGN-401, with ten participants receiving the 1E15 vg dose, demonstrating its commitment to advancing clinical development[27]. - All pediatric participants in the trial gained an aggregate of 35 developmental milestones across core clinical domains of Rett syndrome[53]. - As of October 30, 2025, 80% of participants with at least 12 months of follow-up met the primary endpoint responder definition in the Embolden trial[54]. - NGN-401 has been generally well-tolerated at the 1E15 vg dose, with all treatment-related adverse events being Grade 1 or Grade 2 in severity[55]. - The Embolden Phase 3 trial has enrolled 100% of participants, with over 50% already dosed, and is expected to complete dosing by Q2 2026[59]. - The Phase 1/2 trial showed no cases of hemophagocytic lymphohistiocytosis (HLH) at the 1E15 vg dose, with enhanced monitoring protocols in place[57]. - The primary endpoint of the Embolden trial requires a minimum response rate of 35% (7 out of 20 patients) to reject the null hypothesis[58]. Research Collaborations - The Master Research Collaboration with the University of Edinburgh has been extended to December 2026, supporting research and pipeline development activities[31]. - The company has entered into a Master Collaboration Agreement with the University of Edinburgh, which was extended for an additional 33 months in November 2023[90]. - Under the March 2022 Edinburgh License Agreement, the company obtained an exclusive worldwide license to certain patents, with royalties payable on a product-by-product basis[91]. Regulatory and Compliance - The FDA and other regulatory authorities extensively regulate the research, development, and approval processes for biologics products[95]. - The company must submit an IND to the FDA before beginning any clinical trial, which must become effective within 30 days unless safety concerns arise[98]. - The FDA began accepting applications for the START pilot program in 2024 to accelerate the development of novel drugs for rare diseases, with NGN-401 for Rett syndrome selected for this program[114]. - NGN-401 has received fast track designation for the treatment of Rett syndrome, allowing for more frequent interactions with the FDA during product development[116]. - The FDA aims to review standard BLA applications within ten months and priority reviews within six months after filing, with potential extensions for additional information requests[109]. - A BLA must include all relevant data from preclinical studies and clinical trials, including both positive and negative results, along with detailed product information[107]. - The FDA may require post-marketing studies to verify clinical benefits for products granted accelerated approval, with potential expedited withdrawal procedures if conditions are not met[117]. - The FDA requires that a BLA or supplement must contain pediatric data to assess safety and effectiveness for all relevant pediatric subpopulations under the Pediatric Research Equity Act[108]. - The FDA may refuse to file a BLA deemed incomplete, requiring resubmission with additional information[109]. - The manufacturing process for a product must comply with cGMP requirements to ensure consistent quality and safety before BLA approval[110]. - The FDA conducts inspections of manufacturing facilities and clinical sites to ensure compliance with regulatory standards before approving a BLA[110]. - The FDA's priority review aims to take action on marketing applications within six months, compared to ten months under standard review, although the company has not sought this designation for any product candidates to date[120]. - The company has received orphan drug designation for NGN-401, which is intended for a rare disease affecting fewer than 200,000 individuals in the U.S.[122]. - Orphan drug exclusivity grants seven years of exclusive approval for the product if it is the first to receive FDA approval for the designated condition[123]. - The FDA may withdraw approval if regulatory compliance is not maintained, which could lead to significant consequences including product recalls and fines[127]. - The BPCIA allows for a 12-year exclusivity period for reference biologics, during which biosimilars cannot be approved[133]. - Patent term extensions of up to five years may be applied for after BLA approval, compensating for time lost during the FDA regulatory process[138]. Market and Pricing Regulations - The company faces significant uncertainty regarding coverage and reimbursement for its pharmaceutical products, which is essential for successful commercialization[156][157]. - Third-party payors are increasingly challenging the prices of medical products, which could limit sales of approved products[157]. - Obtaining coverage and adequate reimbursement for products administered under physician supervision may be particularly difficult due to higher associated prices[158]. - The company must provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance of consistent coverage and reimbursement[157]. - The company is also subject to federal price reporting laws, which require complex pricing metrics to be reported to government programs[146]. - The U.S. government is increasing scrutiny on drug pricing practices, leading to potential Congressional inquiries and new regulations aimed at reducing prescription drug costs[167]. - Individual states are implementing regulations to control pharmaceutical pricing, which may negatively impact the company's financial condition and operations[169]. International Regulations - Clinical trials for marketing authorization in the EU must comply with EU regulations, including the new Clinical Trials Regulation that took effect on January 31, 2022[180]. - The centralized authorization procedure allows for a single marketing authorization (MA) valid across all EU Member States, with a typical evaluation timeframe of 210 days, which can be reduced to 150 days for accelerated assessments[189][190]. - Innovative medicinal products, classified as New Chemical Entities (NCE), are eligible for eight years of data exclusivity and ten years of marketing exclusivity in the EU[199]. - A conditional marketing authorization can be granted in exceptional circumstances, valid for one year and renewable annually, provided specific obligations are met[198]. - The European Commission's proposal for pharmaceutical legislation reform includes shortening data exclusivity from eight years to six years and extending market exclusivity for orphan medicines under certain conditions[205]. - The Medicines and Healthcare Products Regulatory Agency (MHRA) aims to reach a decision on MA applications within 210 "clock-on" days, excluding any "clock-stops" for applicant responses[185]. - The IRP, effective January 1, 2024, allows for fast-tracked reviews of medicinal products approved in other jurisdictions, replacing existing EU reliance procedures[186]. - The UK government has adopted the Medicines and Medical Devices Act 2021 to update regulatory frameworks post-Brexit, impacting human medicines and clinical trials[226]. - Pediatric Investigation Plans (PIPs) are mandatory for new medicinal products in the EU, with compliance required for marketing authorization applications[209]. - The EMA's pharmacovigilance rules impose obligations on marketing authorization holders to monitor and report on the safety of medicinal products[215]. - Non-compliance with pharmacovigilance obligations can lead to the variation, suspension, or withdrawal of marketing authorizations[216]. - The advertising and promotion of medicinal products must comply with the approved Summary of Product Characteristics (SmPC) to avoid off-label promotion[219]. - The company must ensure compliance with EU laws governing clinical trials and marketing authorizations to avoid penalties[213].